Systemic T-cell activation and interferon-γ activity in indeterminate severe hepatitis (iSH) are reminiscent of hemophagocytic lymphohistiocytosis (HLH): Implications for T-cell and interferon-γ directed therapies.
Our data suggests flow-based T-cell activation markers could help in early identification and risk stratification for targeted intervention in patients with iSH.